| Literature DB >> 26822089 |
Huina Zhang1, Jian Liu2, Dan Qu2, Li Wang2, Jiang-Yun Luo2, Chi Wai Lau2, Pingsheng Liu3, Zhen Gao2, George L Tipoe4, Hung Kay Lee5, Chi Fai Ng6, Ronald Ching Wan Ma7, Xiaoqiang Yao2, Yu Huang8.
Abstract
Endothelial dysfunction plays a crucial role in the development of diabetic vasculopathy. Our initial quantitative PCR results showed an increased miR-200c expression in arteries from diabetic mice and patients with diabetes. However, whether miR-200c is involved in diabetic endothelial dysfunction is unknown. Overexpression of miR-200c impaired endothelium-dependent relaxations (EDRs) in nondiabetic mouse aortas, whereas suppression of miR-200c by anti-miR-200c enhanced EDRs in diabetic db/db mice. miR-200c suppressed ZEB1 expression, and ZEB1 overexpression ameliorated endothelial dysfunction induced by miR-200c or associated with diabetes. More importantly, overexpression of anti-miR-200c or ZEB1 in vivo attenuated miR-200c expression and improved EDRs in db/db mice. Mechanistic study with the use of COX-2(-/-) mice revealed that COX-2 mediated miR-200c-induced endothelial dysfunction and that miR-200c upregulated COX-2 expression in endothelial cells through suppression of ZEB1 and increased production of prostaglandin E2, which also reduced EDR. This study demonstrates for the first time to our knowledge that miR-200c is a new mediator of diabetic endothelial dysfunction and inhibition of miR-200c rescues EDRs in diabetic mice. These new findings suggest the potential usefulness of miR-200c as the target for drug intervention against diabetic vascular complications.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26822089 DOI: 10.2337/db15-1067
Source DB: PubMed Journal: Diabetes ISSN: 0012-1797 Impact factor: 9.461